SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors brace for the highly anticipated 80th event trigger in the REGAL Phase 3 trial, which will unblind the survival data and potentially catalyze a major acquisition. The community is intensely debating the stock's valuation, fueled by speculation regarding a multi-billion dollar buyout from big pharma players and significant upward pressure from elevated short borrow fees.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense community discussion following reports of a partnership with Shift4 Payments, which has sparked speculation about broader enterprise software adoption. While bulls emphasize the company's expanding role in AI-driven data analytics and government contracts, bears remain focused on valuation concerns and the stock's recent choppy price action within a wider consolidation phase.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant upward momentum as investors speculate on upcoming FDA peptide reviews and growth from new product integrations. The stock is currently a major focus for retail and institutional traders, with the community actively debating potential short-squeeze mechanics and the company's ability to maintain its recent price breakout.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders debate its potential for a rebound, with the community split between those accumulating in anticipation of ecosystem expansion and others dismissing the project as a speculative gamble. This heightened interest is largely driven by persistent discussions around the token's role within Japan's blockchain infrastructure and its ability to weather broader market volatility.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors debate the impact of the company's new C$150 million At-The-Market equity program, with some viewing the dilution as a necessary step to fund R&D while others fear further stock price collapse. The community remains deeply divided, balancing excitement over the company's post-quantum cryptography pilots and hardware development against concerns regarding its lack of revenue and the volatile public feud between company leadership.

FreeCast, Inc. operates an online video streaming platform. Its cloud entertainment platform comprises the largest aggregated library of free and pay-per-view video-on-demand, streaming channels, live events, radio stations, music videos and online games. The company was founded by William A. Mobley, Jr. on June 21, 2011 and is headquartered in Orlando, FL.

Freecast Inc - Ordinary Shares - Class A

Freecast Inc

Freecast Inc. is experiencing extreme volatility and intense retail interest driven by a strategic reseller agreement with Starlink Business, fueling a massive short squeeze momentum. While retail bulls are aggressively targeting a continued rally and celebrating significant gains, community discourse remains sharply polarized between those betting on further upside potential and skeptics warning of imminent dilution risks and weak fundamentals.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is rallying as investors await critical Phase 3 VELA 52-week clinical data, which many anticipate will confirm the company's leading position in the Hidradenitis Suppurativa market. The community is heavily focused on the potential for a major valuation rerating or acquisition, with discussions centering on whether the upcoming trial results will trigger an M&A event or validate the asset's 'best-in-class' therapeutic potential.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is generating significant market buzz following the announcement of a collaboration with Midjourney to integrate its ultrasound-on-chip technology into AI-powered full-body scanners. While the community is actively debating the stock's long-term potential as a semiconductor player versus the risk of hype-driven volatility, sentiment is split between investors anticipating an epic short squeeze and skeptics warning of a classic sell-the-news event.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and intense debate among investors as community members weigh the stock's long-term potential in the voice AI sector against concerns over insider share disposals, acquisition-related dilution, and short-seller pressure. While bulls point to recent industry recognition as an AI leader and a growing backlog of enterprise contracts as signs of an impending reversal, others remain skeptical, focusing on the company's path to profitability and lack of immediate catalysts to spark a sustained rally.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda, which focuses on developing solid-state battery technology and manufacturing processes. Community sentiment is largely optimistic, with investors highlighting the validation from a major OEM as a de-risking catalyst, while debates persist regarding the timeline for commercialization and the distinction between research agreements and direct supply contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.read more...

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the studys dual primary endpoints, demonstrating statistically significant and clinically...

ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe

Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug...

Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present...

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com...

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the companys psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data...

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry productsLYBALVI (olanzapine and samidorphan) and ARISTADA (aripiprazole lauroxil)and its ongoing involvement in sleep medicine. The data presented...

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$44.99
Prev Close	$44.51
Open	$45.25
Dividend Yield	0.00%
50-Day Moving Average	$37.84
Beta	0.65
Avg. Volume	2.28M
PE Ratio	50.02

52-Week High	$45.76
52-Week Low	$25.17
Market Capitalization	$7.5B
EPS (Annual)	$1.43
Price to Book	4.28
Revenue Per Employee	$719,950.73

ALKSAlkermes plc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALKS News